Company:  LUCID DIAGNOSTICS INC. (LUCD)
Form Type:  S-1/A
Filing Date:  10/8/2021 
CIK:  0001799011 
Address:  ONE GRAND CENTRAL PLACE
SUITE 4600
 
City, State, Zip:  NEW YORK, New York 10165 
Telephone:  212-949-4319 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.15  
Change: 
-0.09 (-4.02%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$81.55M
Trade LUCD now with 

© 2022  
Description of Business
Lucid Diagnostics, Inc. ("Lucid") is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease ("GERD"), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma ("EAC"). References in this Form 10-K to "we," "us" and "our" are to Lucid and, unless the context otherwise requires, its subsidiaries. We believe that our lead products, the EsoGuard® Esophageal DNA Test performed on samples collected with the EsoCheck® Esophageal Cell Collection Device, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.
Register and access this filing in:     
  FORM S-1/A
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE
    PART II
      Item 13. Other Expenses of Issuance and Distribution.
      Item 14. Indemnification of Directors and Officers.
      Item 15. Recent Sales of Unregistered Securities.
      Item 16. Exhibits and Financial Statement Schedules.
      Item 17. Undertakings.
    SIGNATURES
  EXHIBIT 1.1
    Signature Page
  EXHIBIT 10.1
  EXHIBIT 10.8
  EXHIBIT 10.9
  EXHIBIT 10.12